Cancer drug olaparib gets a makeover: which pill works best?

NCT ID NCT00777582

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms in a random order to compare their bioavailability and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (AZD2281)
What this could lead to: If successful, this could help identify the best oral form of olaparib for future use in cancer treatment.
What could go wrong: This is an early-phase trial focused on drug absorption, not on curing cancer. Results may not lead to improved outcomes for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Research Site

Randwick, 2031, Australia
Research Site

Leuven, 3000, Belgium
Research Site

Bellinzona, CH-6500, Switzerland
Research Site

Edinburgh, EH4 2XR, United Kingdom
Research Site

London, NW1 2PG, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Newcastle upon Tyne, NE7 7DN, United Kingdom
Research Site

Northwood, HA6 2RN, United Kingdom
Research Site

Oxford, OX3 7LE, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.